CoChat

Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis

Open access

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In 2006, the National Institute of Clinical and Health Excellence (NICE) guidelines for Obsessive Compulsive Disorder (OCD) recommended anti-psychotics as a class for SSRI treatment resistant OCD. The article aims to systematically review and conduct a meta-analysis on the clinical effectiveness of atypical anti-psychotics augmenting an SSRI. METHODS: Studies that were double-blind randomized controlled trials of an atypical antipsychotic against a placebo, for a minimum of 4 weeks, in adults with OCD, were included. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores were the primary outcome measure. Inclusion criteria included Y-BOCS score of 16 or more and at least one adequate trial of a SSRI or clomipramine for at least 8 weeks prior to randomization. Data sources included Medline, Embase, PsycINFO, Cochrane Database of Systematic Reviews (CDSR), trial registries and pharmaceutical databases and manufacturers up to September 2013. Forest-plots were drawn to display differences between drug and placebo on the Y-BOCS. RESULTS: Two studies found aripiprazole to be effective in the short-term. There was a small effect-size for risperidone or anti-psychotics in general in the short-term. We found no evidence for the effectiveness of quetiapine or olanzapine in comparison to placebo. CONCLUSIONS: Risperidone and aripiprazole can be used cautiously at a low dose as an augmentation agent in non-responders to SSRIs and CBT but should be monitored at 4 weeks to determine efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-014-0317-5

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Meta-analysis of all anti-psychotics for obsessive-compulsive disorder.
Figure 1 Meta-analysis of all anti-psychotics for obsessive-compulsive disorder.CC BY · PubMed Central
Figure 2 Meta-analysis of risperidone treatment vs placebo for obsessive-compulsive disorder.
Figure 2 Meta-analysis of risperidone treatment vs placebo for obsessive-compulsive disorder.CC BY · PubMed Central
Figure 3 Meta-analysis of olanzapine treatment vs placebo for obsessive-compulsive disorder.
Figure 3 Meta-analysis of olanzapine treatment vs placebo for obsessive-compulsive disorder.CC BY · PubMed Central
Figure 4 Meta-analysis of quetiapine treatment vs placebo for obsessive-compulsive disorder.
Figure 4 Meta-analysis of quetiapine treatment vs placebo for obsessive-compulsive disorder.CC BY · PubMed Central
Figure 5 Meta-analysis of aripiprazole treatment vs placebo for obsessive-compulsive disorder.
Figure 5 Meta-analysis of aripiprazole treatment vs placebo for obsessive-compulsive disorder.CC BY · PubMed Central
Figure 6 Flow diagram of study selection for meta-analysis.
Figure 6 Flow diagram of study selection for meta-analysis.CC BY · PubMed Central
Figure 7 Funnel plot for all studies.
Figure 7 Funnel plot for all studies.CC BY · PubMed Central
Figure 8 Meta-analysis of risperidone treatment vs placebo for obsessive-compulsive disorder, measured as odds ratios.
Figure 8 Meta-analysis of risperidone treatment vs placebo for obsessive-compulsive disorder, measured as odds ratios.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 1

  1. Tatari F, Khazaei H, Jahandar F, Rezaei M: Effect of adding risperidone to fluoxetine in treatment of obsession compulsion disorder patients. Life Sci J. 2013, 10 (11s): 153-157.

Cited by

See all 174

Metadata

Authors
Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J.
Affiliations
  • King's College London (GB)
  • London School of Hygiene & Tropical Medicine (GB)
Corresponding author
Veale, David
Venue
BMC Psychiatry
Published
2014-11-29
Volume
14
Issue
1
Pages
317-317
ISSN
1471-244X (ISSN-L)
OpenAlex
W2067425354
Cited by
162
References
44
Citations by year
2026: 16 · 2025: 10 · 2024: 10 · 2023: 8 · 2022: 8 · 2021: 11 · 2020: 19 · 2019: 24 · 2018: 16 · 2017: 15 · 2016: 14 · 2015: 11
FWCI
2.03
Type
journal article
Language
en
Open access
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • South London and Maudsley NHS Foundation Trust
  • National Institute for Health and Care Research
  • King's College London
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
obsessive-compulsive disorder, atypical antipsychotics, SSRI augmentation, treatment-resistant OCD, aripiprazole, risperidone, quetiapine, olanzapine, Yale-Brown Obsessive Compulsive Scale, clomipramine, cognitive behavioral therapy
MeSH terms
Aripiprazole, Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Clomipramine, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Humans, Obsessive-Compulsive Disorder, Piperazines, Antipsychotic Agents, Quinolones, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12888-014-0317-5
The paper
Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. https://doi.org/10.1186/s12888-014-0317-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.